Epix Pharmaceuticals Company Overview and Financial Data

Epix Pharmaceuticals is a biopharmaceutical company that has been working on developing innovative treatments for various medical conditions. Epix was founded in 1997.

The company's main focus has been on developing treatments for cardiovascular diseases, including hypertension and heart failure.

Epix Pharmaceuticals has developed a portfolio of products, including oral antiplatelet agents and vasopressin receptor antagonists.

In terms of financial data, Epix Pharmaceuticals has received significant funding from various investors, including venture capital firms and institutional investors.

Epix Pharmaceuticals is a biopharmaceutical company that was acquired by Indivior in 2016.

Epix Pharmaceuticals was a US-based biopharmaceutical company that focused on the development of treatments for central nervous system disorders.

The company had a pipeline of several products, including a potential treatment for multiple sclerosis.

Epix Pharmaceuticals had a strong research and development team that worked on developing new treatments for various diseases.

The company had a significant presence in the US market, with a strong network of partners and collaborators.

EPIX Pharmaceuticals generated $17.7 million in annual revenue in 2025.

We can see that the company's revenue has been steadily growing over the years, but the exact figures for previous years are not provided.

Unfortunately, we don't have information on the company's current market value, but we do know that its annual revenue was $17.7 million in 2025.

EPIX Pharmaceuticals' financials are a key aspect of understanding the company's overall performance and growth potential.

Epix Pharmaceuticals is a biopharmaceutical company that has been focused on developing innovative treatments for various diseases.

The company was founded in 2007 by a team of experienced pharmaceutical professionals.

Epix Pharmaceuticals is headquartered in Cambridge, Massachusetts, a hub for biotech and pharmaceutical companies.

The employment count at EPIX Pharmaceuticals is a relatively small team of 12 people.

This is a much smaller team than many other companies in the industry, which can be beneficial for collaboration and decision-making.

EPIX Pharmaceuticals has a tight-knit team that allows for efficient communication and problem-solving.

Having a smaller team also means that each employee has a significant impact on the company's overall success.

12 people is a manageable number for a company, making it easier to maintain a positive work culture and employee satisfaction.

This small team is likely to be a key factor in the company's ability to innovate and adapt to changing market conditions.

A team of 12 people can also be more agile and responsive to customer needs, which is essential for a company that wants to build strong relationships with its clients.

The small team size at EPIX Pharmaceuticals may also contribute to lower overhead costs and a more streamlined operations process.

This can be beneficial for the company's bottom line and allow for more investment in research and development.

A team of 12 people can also be more approachable and easier to work with for partners and collaborators.

Overall, the small team size at EPIX Pharmaceuticals is likely to be a key factor in the company's success and ability to achieve its goals.

Worth a look: Johnson & Johnson - Merck Consumer Pharmaceuticals Company

EPIX Pharmaceuticals is based in Lexington, Massachusetts. This is a significant detail that can help us understand the company's background and operations.

One of the companies that outranks EPIX Pharmaceuticals in terms of funding is Jazz Pharmaceuticals, which has received $265M in total funding. This is a notable difference in the amount of resources available to these companies.

Here's a list of the top 5 companies in terms of funding, based on the article:

It's worth noting that EPIX Pharmaceuticals has a lower Tracxn Score of 21/100, which indicates a lower level of success or progress compared to the other companies listed.

Xiang Yu is the Director, Medicinal Chemistry of EPIX Pharmaceuticals. He brings a wealth of experience to this role.

EPIX Pharmaceuticals is fortunate to have Xiang Yu at the helm of its medicinal chemistry department.

Epix Pharmaceuticals has a notable presence in the intellectual property landscape. They have filed 4 patents.

Their patent filings have yielded a grant, which is a significant achievement. This suggests that their innovative work has been recognized and validated.

One of their patents was filed on 9/19/2008 and granted on 12/20/2011. This patent is titled "S1p receptor modulating compounds and use thereof".

This patent has a broad scope, covering topics such as G protein coupled receptors, autoimmune diseases, monoclonal antibodies, inflammations, and immunology.

EPIX Pharmaceuticals has been involved in several mergers and acquisitions since 2007. These transactions include partnerships, alliances, and investments, which have helped sustain the company's competitive advantage.

The company's Mergers and Acquisitions report, available from USD $350, provides a comprehensive breakdown of these activities. This report includes detailed information on various financial transactions undertaken by EPIX Pharmaceuticals and its subsidiaries since 2007.

The report offers valuable insights into EPIX Pharmaceuticals' growth strategies through its organic and inorganic activities.

Take a look at this: List of Largest Pharmaceutical Mergers and Acquisitions

Essa Pharma's stock price plummeted by a staggering 66% before the company announced its shutdown. This drastic decline is a clear indicator of the company's financial struggles.

The shutdown was likely a result of the company's inability to secure funding for its operations. Essa Pharma's financial struggles were evident in its stock performance.

The company's stock price was already volatile, but the 66% drop is a stark reminder of the risks involved in investing in struggling companies.

For another approach, see: Acceleron Pharma

EPIX Pharmaceuticals, Inc. has been quite active in mergers and acquisitions. The company's Mergers Acquisitions MA, Partnerships Alliances and Investments report is priced from USD $350.

MarketLine's report on EPIX Pharmaceuticals, Inc. offers a comprehensive breakdown of the company's organic and inorganic growth activity. This report includes detailed information on mergers and acquisitions, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by EPIX Pharmaceuticals, Inc. since January 2007.

The report provides intelligence on EPIX Pharmaceuticals, Inc.'s MA, strategic partnerships and alliances, capital raising and private equity transactions. It also includes information about key financial and legal advisors for EPIX Pharmaceuticals, Inc.'s financial deals transactions.

A unique perspective: Charlesbank Capital Partners

Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity are also included in the report. This information can be useful for tracking competitors' business structure and growth strategies.

The report is available for purchase from MarketLine for a price of USD $350.

Epix Pharmaceuticals has raised funding over 1 round, which suggests that the company has secured financial support at least once.

Their main institutional investor is Astellas Venture Management, a key partner in their growth.

This funding has likely helped Epix Pharmaceuticals move forward with their goals and objectives, but the specifics of their plans are not detailed here.

Hedge Funds Stop Buying ESSA Pharma Inc, marking a shift in investment strategies for these high-risk, high-reward funds.

On October 19th, 2021, a notable change in investment behavior was reported, with hedge funds ceasing to buy ESSA Pharma Inc. (EPIX).

This decision may be attributed to various market factors, but the exact reasons are not specified in the report.

The article "Hedge Funds Are Done Buying ESSA Pharma Inc. (EPIX)" dated October 19th, 2021, highlights this significant change in investment trends.

Investors should take note of this shift, as it may impact the overall market dynamics and investment opportunities.

A unique perspective: Open Market

Epix Pharmaceuticals has raised funding over 1 round. This shows that the company has been able to secure financial support at least once.

Epix Pharmaceuticals has 1 institutional investor - Astellas Venture Management. This suggests that the company has a strong partnership with a reputable investor.

Having a single institutional investor can be a good thing, as it provides a steady source of funding and expertise.